Insurance and Cost-Related Access Barriers to Specialty Oral Anticancer Medications for Blood Cancers in a Nationwide Sample of Medicare and Commercially Insured Patients
Journal of Clinical Oncology · 2026
DOI: 10.1200/jco-26-00247 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Jalpa A Doshi und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Pennsylvania, Philadelphia, PA. Hauptthemen laut MEDLINE: Medicare, Antineoplastic Agents, Health Services Accessibility, Insurance, Health. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Specialty oral anticancer medications (SOAMs) improve survival across blood cancers, but access challenges persist. This study examined approval and fill rates of SOAM prescriptions indicated for blood cancers in a nationwide sample of Medicare and commercially insured patients. METHODS Using nationwide claims, we identified patients with ≥1 new SOAM prescription during 2022. Outcomes included whether a prescription for a new SOAM was (1) rejected by the insurer, (2) approved but not filled by the patient, or (3) approved and filled, at both initial presentation and within 90 days. Among rejected prescriptions, we examined rejection reasons. Among approved prescriptions, we compared fill rates across out-of-pocket (OOP) cost levels. Adjusted outcomes were estimated using logistic regressions. RESULTS The study included 12,134 patients (61.0% Medicare, 39.0% commercial) with an SOAM prescription. Initially, very few prescriptions were both approved and filled (9.6%, Medicare; 4.0%, commercial). Insurers initially rejected most prescriptions (64.9% for Medicare, 84.0% for commercial), frequently due to prior authorization or formulary restrictions. By 90 days, approval rates rose to 85.0% (Medicare) and 62.8% (commercial), but many approved prescriptions were never filled; ultimately, only 54.5% of Medicare patients and 45.5% of commercial patients both received insurer approval and filled their prescription. Fill rates dropped sharply when OOP costs exceeded $175 in US dollars (USD), with the lowest rates observed at OOP costs of $500.01–$2,000 USD for Medicare patients (29.2%) and at ≥$2,000 USD for commercially insured patients (21.6%). Adjusted rates were similar to unadjusted rates. CONCLUSION This study found substantial access barriers to SOAMs, particularly among commercially insured patients. Even after insurer approval, many patients never filled their prescription. This highlights the importance of addressing both payer-level restrictions and patient-level affordability challenges to ensure treatment access.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Pennsylvania, Philadelphia, PA.
- Leonard Davis Institute of Health Economics, Philadelphia, PA.
- Independent Consultant, Boston, MA.
- Vagelos College of Physicians and Surgeons, Columbia University, New York, NY.
- Yale University, New Haven, CT.
- University of Texas MD Anderson Cancer Center, Houston, TX.
ORCID-Profile: Jalpa A Doshi, Pengxiang Li, Matthew J Klebanoff, Scott F Huntington, John K Lin
Zitieren
APA
Doshi, J. A., Li, P., Geng, Z., Klebanoff, M. J., Pettit, A. R., Armstrong, K. A., Huntington, S. F., & Lin, J. K. (2026). Insurance and Cost-Related Access Barriers to Specialty Oral Anticancer Medications for Blood Cancers in a Nationwide Sample of Medicare and Commercially Insured Patients. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00247
Vancouver
Doshi JA, Li P, Geng Z, Klebanoff MJ, Pettit AR, Armstrong KA, et al. Insurance and Cost-Related Access Barriers to Specialty Oral Anticancer Medications for Blood Cancers in a Nationwide Sample of Medicare and Commercially Insured Patients. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-00247
BibTeX
@article{Doshi2026,
author = {Doshi, Jalpa A and Li, Pengxiang and Geng, Zhi and Klebanoff, Matthew J and Pettit, Amy R and Armstrong, Katrina A and Huntington, Scott F and Lin, John K},
title = {Insurance and Cost-Related Access Barriers to Specialty Oral Anticancer Medications for Blood Cancers in a Nationwide Sample of Medicare and Commercially Insured Patients},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-26-00247}
}
EUVIMED